Study summary · research use only
[Treatment of osteoporosis with PTH]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This commentary discusses teriparatide, described as the only available bone anabolic drug in practice and an N-terminal fragment of parathyroid hormone (PTH), administered to patients with osteoporosis. The abstract states its mode of action is pharmacological rather than physiological and that treatment is not equivalent to hormone replacement. The authors emphasize that physicians should evaluate its clinical standing relative to other anti-osteoporosis drugs, noting it is not classified as a first-line drug.
Abstract
Teriparatide is an only available bone anabolic drug in practice. It is a N-terminal fragment of parathyroid hormone (PTH) . Mode of actions of teriparatide is pharmacological but not physiological as it is administered to patients with osteoporosis. Physicians need to understand the fact that treatment with teriparatide is not just like a hormone replacement. They also should administer teriparatide to their patients after rigorous evaluation of its clinical superiority to other anti-osteoprosis drugs, because it is not classified as a first-line drug.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.